HUP0202332A2 - Pyrazole compositions useful as inhibitors of erk - Google Patents
Pyrazole compositions useful as inhibitors of erkInfo
- Publication number
- HUP0202332A2 HUP0202332A2 HU0202332A HUP0202332A HUP0202332A2 HU P0202332 A2 HUP0202332 A2 HU P0202332A2 HU 0202332 A HU0202332 A HU 0202332A HU P0202332 A HUP0202332 A HU P0202332A HU P0202332 A2 HUP0202332 A2 HU P0202332A2
- Authority
- HU
- Hungary
- Prior art keywords
- erk
- inhibitors
- compositions useful
- pyrazole compositions
- pyrazole
- Prior art date
Links
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18050600P | 2000-02-05 | 2000-02-05 | |
US19195600P | 2000-03-24 | 2000-03-24 | |
US24293500P | 2000-10-24 | 2000-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0202332A2 true HUP0202332A2 (en) | 2002-10-28 |
Family
ID=27391289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0202332A HUP0202332A2 (en) | 2000-02-05 | 2001-02-05 | Pyrazole compositions useful as inhibitors of erk |
Country Status (19)
Country | Link |
---|---|
US (4) | US6528509B1 (hu) |
EP (1) | EP1200422A2 (hu) |
JP (1) | JP4783532B2 (hu) |
KR (1) | KR20010111298A (hu) |
CN (1) | CN1362953A (hu) |
AU (1) | AU782775B2 (hu) |
BG (1) | BG106054A (hu) |
BR (1) | BR0104424A (hu) |
CA (1) | CA2369504C (hu) |
CZ (1) | CZ20013540A3 (hu) |
HK (1) | HK1046276A1 (hu) |
HU (1) | HUP0202332A2 (hu) |
IL (1) | IL145757A (hu) |
LT (1) | LT4981B (hu) |
NO (1) | NO322745B1 (hu) |
NZ (1) | NZ514583A (hu) |
SK (1) | SK14082001A3 (hu) |
TR (1) | TR200103787T1 (hu) |
WO (1) | WO2001057022A2 (hu) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
EP1200422A2 (en) * | 2000-02-05 | 2002-05-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
US6436915B1 (en) | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
HU227882B1 (hu) | 2000-08-10 | 2012-05-29 | Mitsubishi Tanabe Pharma Corp | Prolinszármazékok és gyógyszerként való alkalmazásuk |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
DE60120193T2 (de) | 2000-09-15 | 2007-03-29 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinasehemmer |
US6495582B1 (en) * | 2000-09-15 | 2002-12-17 | Vertex Pharmaceuticals Incorporated | Isoxazole compositions useful as inhibitors of ERK |
EP1319001A1 (en) | 2000-09-22 | 2003-06-18 | Smithkline Beecham Plc | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
ATE528303T1 (de) * | 2000-12-21 | 2011-10-15 | Vertex Pharma | Pyrazoleverbindungen als proteinkinasehemmer |
US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
DE60238620D1 (de) | 2001-08-03 | 2011-01-27 | Vertex Pharma | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
EP1423382B1 (en) | 2001-08-03 | 2008-04-16 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
MXPA04005204A (es) | 2001-11-30 | 2005-11-04 | Quadra Logic Tech Inc | Derivados de hidrazonipirazol y su uso como terpapeuticos. |
CA2471565C (en) * | 2002-01-10 | 2009-10-27 | Patricia Ann Day-Lollini | Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
SG159380A1 (en) * | 2002-02-06 | 2010-03-30 | Vertex Pharma | Heteroaryl compounds useful as inhibitors of gsk-3 |
DE60332604D1 (de) * | 2002-03-15 | 2010-07-01 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
WO2003091246A1 (en) * | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
CA2494061C (en) * | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
JP4733388B2 (ja) * | 2002-08-02 | 2011-07-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | Gsk−3のインヒビターとして有用なピラゾール組成物 |
EP1388541A1 (en) * | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
EP1551824B1 (en) * | 2002-10-09 | 2007-12-12 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
EP1627043A4 (en) * | 2002-10-23 | 2006-10-11 | Exelixis Inc | MAPK7 AS A BRANCHING METHOD AND MODIFYING METHOD |
BR0317525A (pt) * | 2002-12-20 | 2005-11-16 | Pharmacia Corp | Compostos pirazol acìclico, composição terapêutica e farmacêutica, kit, bem como respectivos usos |
US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
WO2004078261A1 (en) * | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
EP1651612B9 (en) | 2003-07-22 | 2012-09-05 | Astex Therapeutics Limited | 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
DE602004012578T2 (de) * | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
DE10354060A1 (de) * | 2003-11-19 | 2005-06-02 | Merck Patent Gmbh | Pyrrolderivate |
AU2004297235A1 (en) * | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
US7488817B2 (en) * | 2004-02-02 | 2009-02-10 | The Trustees Of The University Of Pennsylvania | Metal complex protein kinase inhibitors |
US7462612B2 (en) | 2004-03-26 | 2008-12-09 | Vertex Pharmaceuticals Incorporated | Pyridine inhibitors of ERK2 and uses thereof |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
EP1778669A2 (en) * | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
FR2876582B1 (fr) * | 2004-10-15 | 2007-01-05 | Centre Nat Rech Scient Cnrse | Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
JP2008520745A (ja) * | 2004-11-22 | 2008-06-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Rhoキナーゼの二環式阻害剤 |
TWI427077B (zh) * | 2004-12-30 | 2014-02-21 | Astex Therapeutics Ltd | 吡唑化合物及其用途和含有彼之藥學組成物 |
EP1836188A1 (en) * | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
WO2006070202A1 (en) * | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1904457B1 (en) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP2007000061A (ja) * | 2005-06-23 | 2007-01-11 | Sumitomo Chemical Co Ltd | 昆虫由来のc−Junアミノ末端リン酸化酵素活性に関わる有害生物の生理状態に変化を与える薬剤 |
US7737151B2 (en) * | 2005-08-18 | 2010-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
CA2627830A1 (en) * | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
PT1966151E (pt) * | 2005-12-13 | 2011-12-20 | Schering Corp | Derivados de indazol policíclicos que são inibidores de erk |
JP5474354B2 (ja) | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
DE602007009932D1 (de) | 2006-02-16 | 2010-12-02 | Schering Corp | Pyrrolidin-derivate als erk-hemmer |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
US8435970B2 (en) | 2006-06-29 | 2013-05-07 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea |
SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP2010509231A (ja) * | 2006-11-02 | 2010-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なアミノピリジンおよびアミノピリミジン |
AU2007333650A1 (en) * | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
EP2132178B1 (en) * | 2006-12-20 | 2015-08-19 | Merck Sharp & Dohme Corp. | Jnk inhibitors |
CA2673683C (en) | 2007-01-11 | 2014-07-29 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
EP2114388B1 (en) * | 2007-02-07 | 2015-05-20 | GlaxoSmithKline LLC | Inhibitors of akt activity |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
ES2435997T3 (es) * | 2007-03-09 | 2013-12-26 | Vertex Pharmaceuticals, Inc. | Aminopirimidinas útiles como inhibidores de las proteínas cinasas |
AU2008226461A1 (en) | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
EP2137183B1 (en) * | 2007-03-09 | 2011-09-28 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
JP2010523700A (ja) | 2007-04-13 | 2010-07-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリミジン |
CN101801959A (zh) * | 2007-05-02 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
CA2685876A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
EP2155730A2 (en) * | 2007-05-02 | 2010-02-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2008147626A2 (en) * | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
CN101772501A (zh) * | 2007-06-18 | 2010-07-07 | 先灵公司 | 杂环化合物及其作为erk抑制剂的用途 |
CN101790532B (zh) * | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 5-氟-1H-吡唑并[3,4-b]吡啶-3-胺及其衍生物的制备方法 |
CA2710039C (en) * | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
CA2715658C (en) | 2008-02-15 | 2016-07-19 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
EP2260031B1 (en) | 2008-02-21 | 2015-10-07 | Merck Sharp & Dohme Corp. | Compounds that are erk inhibitors |
BRPI0910921B1 (pt) | 2008-04-16 | 2022-06-21 | Portola Pharmaceuticals, Inc | Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
US8106039B2 (en) * | 2008-04-30 | 2012-01-31 | The Trustees Of The University Of Pennsylvania | Metal complex phosphatidyl-inositol-3-kinase inhibitors |
WO2009158371A1 (en) * | 2008-06-26 | 2009-12-30 | Smithklike Beecham Corporation | Inhibitors of akt activity |
WO2009158374A2 (en) * | 2008-06-26 | 2009-12-30 | Smithkline Beecham Corporation | Inhibitors of akt activity |
EP2303277A4 (en) * | 2008-06-26 | 2011-08-17 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
EP3023426A1 (en) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
MX2011002312A (es) * | 2008-09-03 | 2011-04-26 | Vertex Pharma | Co-cristales y formulaciones farmaceuticas que comprenden los mismos. |
AU2010281404A1 (en) * | 2009-07-28 | 2012-02-09 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8198285B2 (en) | 2010-01-19 | 2012-06-12 | Astrazeneca Ab | Pyrazine derivatives |
EP2552915B1 (en) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
EP2635557A2 (en) | 2010-11-01 | 2013-09-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
CA2856301C (en) | 2011-11-23 | 2020-10-06 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
KR101600579B1 (ko) * | 2014-06-25 | 2016-03-07 | 한국생명공학연구원 | 피라졸 아마이드 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
CA2975048C (en) | 2015-01-30 | 2024-01-02 | Biomed Valley Discoveries, Inc. | Crystalline forms of c21h22ci2n4o2 |
US10864179B2 (en) | 2015-10-01 | 2020-12-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
WO2017097216A1 (zh) * | 2015-12-07 | 2017-06-15 | 杭州雷索药业有限公司 | 五元杂环酰胺类wnt通路抑制剂 |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
EP3805217A4 (en) * | 2018-06-08 | 2022-03-23 | Betta Pharmaceuticals Co., Ltd | ERK INHIBITOR AND USES THEREOF |
US11795160B2 (en) * | 2019-02-22 | 2023-10-24 | Insilico Medicine Ip Limited | Kinase inhibitors |
US20220213119A1 (en) | 2019-03-28 | 2022-07-07 | Jiangsu Hengrui Medicine Ca, Lid. | Thienoheterocyclic derivative, preparation method therefor and medical use thereof |
TW202102505A (zh) | 2019-03-29 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用 |
US20220204512A1 (en) | 2019-05-24 | 2022-06-30 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines |
JP2023543080A (ja) | 2020-09-29 | 2023-10-12 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ピロロ複素環系誘導体の結晶及びその製造方法 |
TW202245753A (zh) | 2021-02-24 | 2022-12-01 | 香港商英科智能有限公司 | 用於治療疾病之類似物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2707295A1 (fr) * | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
JP3734180B2 (ja) * | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
AU7726898A (en) * | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
EP0983260A2 (en) * | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
EP1200422A2 (en) * | 2000-02-05 | 2002-05-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
-
2001
- 2001-02-05 EP EP01908911A patent/EP1200422A2/en not_active Withdrawn
- 2001-02-05 IL IL145757A patent/IL145757A/en not_active IP Right Cessation
- 2001-02-05 TR TR2001/03787T patent/TR200103787T1/xx unknown
- 2001-02-05 CN CN01800374A patent/CN1362953A/zh active Pending
- 2001-02-05 NZ NZ514583A patent/NZ514583A/en unknown
- 2001-02-05 SK SK1408-2001A patent/SK14082001A3/sk unknown
- 2001-02-05 AU AU36723/01A patent/AU782775B2/en not_active Ceased
- 2001-02-05 CA CA002369504A patent/CA2369504C/en not_active Expired - Fee Related
- 2001-02-05 BR BR0104424-9A patent/BR0104424A/pt not_active IP Right Cessation
- 2001-02-05 HU HU0202332A patent/HUP0202332A2/hu unknown
- 2001-02-05 JP JP2001557854A patent/JP4783532B2/ja not_active Expired - Fee Related
- 2001-02-05 WO PCT/US2001/003911 patent/WO2001057022A2/en active IP Right Grant
- 2001-02-05 CZ CZ20013540A patent/CZ20013540A3/cs unknown
- 2001-02-05 KR KR1020017012710A patent/KR20010111298A/ko not_active Application Discontinuation
- 2001-10-04 NO NO20014837A patent/NO322745B1/no not_active IP Right Cessation
- 2001-10-05 US US09/972,437 patent/US6528509B1/en not_active Expired - Lifetime
- 2001-10-17 LT LT2001103A patent/LT4981B/lt not_active IP Right Cessation
- 2001-10-26 BG BG106054A patent/BG106054A/xx unknown
-
2002
- 2002-08-22 US US10/225,719 patent/US6593357B1/en not_active Expired - Lifetime
- 2002-10-16 HK HK02107512.2A patent/HK1046276A1/zh unknown
-
2003
- 2003-01-02 US US10/335,793 patent/US6699865B2/en not_active Expired - Fee Related
- 2003-10-17 US US10/688,613 patent/US7056944B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2001057022A2 (en) | 2001-08-09 |
AU782775B2 (en) | 2005-08-25 |
WO2001057022A3 (en) | 2002-03-07 |
SK14082001A3 (sk) | 2002-03-05 |
CN1362953A (zh) | 2002-08-07 |
IL145757A0 (en) | 2002-07-25 |
US20030225151A1 (en) | 2003-12-04 |
US20040102506A1 (en) | 2004-05-27 |
CA2369504A1 (en) | 2001-08-09 |
HK1046276A1 (zh) | 2003-01-03 |
JP4783532B2 (ja) | 2011-09-28 |
KR20010111298A (ko) | 2001-12-17 |
US6699865B2 (en) | 2004-03-02 |
NZ514583A (en) | 2004-05-28 |
AU3672301A (en) | 2001-08-14 |
EP1200422A2 (en) | 2002-05-02 |
US7056944B2 (en) | 2006-06-06 |
NO322745B1 (no) | 2006-12-04 |
BR0104424A (pt) | 2002-01-08 |
IL145757A (en) | 2007-12-03 |
JP2003522163A (ja) | 2003-07-22 |
NO20014837D0 (no) | 2001-10-04 |
CA2369504C (en) | 2009-01-06 |
LT2001103A (en) | 2002-10-25 |
NO20014837L (no) | 2001-12-04 |
CZ20013540A3 (cs) | 2002-03-13 |
BG106054A (en) | 2002-06-28 |
US6528509B1 (en) | 2003-03-04 |
US20030040536A1 (en) | 2003-02-27 |
US6593357B1 (en) | 2003-07-15 |
TR200103787T1 (tr) | 2002-10-21 |
LT4981B (lt) | 2003-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0202332A2 (en) | Pyrazole compositions useful as inhibitors of erk | |
AU2001236720A1 (en) | Compositions useful as inhibitors of erk | |
HK1081186A1 (en) | Pyrazole compositions useful as inhibitors of gsk-3 | |
SI1686119T1 (sl) | Derivati pirimidin-5-ona kot inhibitorji ldl-pla2 | |
HUP0401819A3 (en) | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them | |
HUP0400641A3 (en) | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them | |
AU7908901A (en) | Indazole derivatives as jnk inhibitors and compositions and methods related thereto | |
AU2002305205A1 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
GB0025782D0 (en) | Use of inhibitors | |
HK1039110A1 (zh) | 以新穎的合成物及組分作為蛋白酶抑制劑 | |
HK1071886A1 (en) | Novel compounds and compositions as cathepsin inhibitors | |
IL152784A0 (en) | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | |
GB0117879D0 (en) | Storage of liquid compositions | |
AU2001245764A1 (en) | Novel compounds and compositions as protease inhibitors | |
AU8323701A (en) | Inhibitors of p38 | |
IL159125A0 (en) | Novel compounds and compositions as cathepsin inhibitors | |
SI1532145T1 (sl) | Pirazolni sestavki, koristni kot inhibitorji GSK-3 | |
AU2002214038A1 (en) | Inhibitors of transglutaminases | |
AU2001283964A1 (en) | Composition for combined use of aromatase inhibitors | |
AU2002221882A1 (en) | Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors | |
EP1430302A4 (en) | Glycosaminoglycan INHIBITORS | |
GB0000916D0 (en) | New compositions of matter | |
IL159135A0 (en) | Novel compounds and compositions as cathepsin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |